M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 26.19 CNY -0.53% Market Closed
Market Cap: 11.3B CNY
Have any thoughts about
Mayinglong Pharmaceutical Group Co Ltd?
Write Note

Mayinglong Pharmaceutical Group Co Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mayinglong Pharmaceutical Group Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
M
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Total Receivables
ÂĄ589.6m
CAGR 3-Years
10%
CAGR 5-Years
-3%
CAGR 10-Years
0%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Receivables
ÂĄ3.3B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Receivables
ÂĄ1.1B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Receivables
ÂĄ7.5B
CAGR 3-Years
-7%
CAGR 5-Years
3%
CAGR 10-Years
10%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Receivables
ÂĄ13.2B
CAGR 3-Years
18%
CAGR 5-Years
13%
CAGR 10-Years
11%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Receivables
ÂĄ172.9m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mayinglong Pharmaceutical Group Co Ltd
Glance View

Market Cap
11.3B CNY
Industry
Pharmaceuticals

In the corridors of China's pharmaceutical industry, Mayinglong Pharmaceutical Group Co Ltd stands out with its roots deeply embedded in history while its branches stretch ambitiously into the future. Founded in 1582 during the Ming Dynasty, this firm has garnered a reputation for its innovative approach to traditional Chinese medicine. The company's evolution from an apothecary serving local communities to a publicly traded enterprise mirrors the dynamic growth of China itself. As the world became increasingly captivated by holistic health solutions, Mayinglong capitalized on its heritage of time-tested remedies, turning ancient formulations into modern products. Their flagship product, Mayinglong Hemorrhoid Ointment, is a renowned success, both domestically and internationally, symbolizing the company's unique ability to blend ancient wisdom with contemporary health needs. Mayinglong's business model thrives on a well-balanced portfolio that includes not only traditional Chinese medicines but also a growing pipeline of innovative pharmaceuticals and healthcare products. Leveraging state-of-the-art technology in their R&D centers, they develop new drugs and therapies that align with both modern health trends and the regulatory demands of global markets. The group's revenue streams are diversified across multiple segments, including over-the-counter products, prescription medications, and personal care items. With a vast distribution network both in China and abroad, Mayinglong benefits from scale and brand recognition. Their strategy is a testament to the harmonious merger of tradition and modernity, driving profitability through a deep understanding of consumer needs paired with scientific innovation.

Intrinsic Value
31.89 CNY
Undervaluation 18%
Intrinsic Value
Price
M

See Also

What is Mayinglong Pharmaceutical Group Co Ltd's Total Receivables?
Total Receivables
589.6m CNY

Based on the financial report for Sep 30, 2024, Mayinglong Pharmaceutical Group Co Ltd's Total Receivables amounts to 589.6m CNY.

What is Mayinglong Pharmaceutical Group Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
0%

Over the last year, the Total Receivables growth was -14%. The average annual Total Receivables growth rates for Mayinglong Pharmaceutical Group Co Ltd have been 10% over the past three years , -3% over the past five years .

Back to Top